Discover the reasons to consider REVLIMID as a FOUNDATION in newly diagnosed multiple myeloma.1,2
REVLIMID® (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.
Indication for REVLIMID + dexamethasone + daratumumab (DRd)
DRd is indicated for the treatment of adult patients with newly diagnosed MM who are ineligible for an autologous stem cell transplant.
Information about DRd does not appear in the REVLIMID full Prescribing Information. Please see the daratumumab full Prescribing Information and Important Safety Information at www.darzalexhcp.com/iv.
Important Dosing Information
References: 1. References with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.3.2022. © 2021 National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed October 27, 2021. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. 2. REVLIMID [package insert]. Summit, NJ: Celgene Corp. 3. Data on file. Celgene Corp; 2020. 4. Daratumumab [package insert]. Horsham, PA: Janssen Biotech, Inc.